DK3445354T3 - Azelainsyreestere ved behandling af insulinresistens - Google Patents

Azelainsyreestere ved behandling af insulinresistens Download PDF

Info

Publication number
DK3445354T3
DK3445354T3 DK17786579.7T DK17786579T DK3445354T3 DK 3445354 T3 DK3445354 T3 DK 3445354T3 DK 17786579 T DK17786579 T DK 17786579T DK 3445354 T3 DK3445354 T3 DK 3445354T3
Authority
DK
Denmark
Prior art keywords
treatment
acid esters
insulin resistance
azelaic acid
azelaic
Prior art date
Application number
DK17786579.7T
Other languages
English (en)
Inventor
Robert T Streeper
Elzbieta Izbicka
Original Assignee
New Frontier Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Frontier Labs Llc filed Critical New Frontier Labs Llc
Application granted granted Critical
Publication of DK3445354T3 publication Critical patent/DK3445354T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK17786579.7T 2016-04-20 2017-04-19 Azelainsyreestere ved behandling af insulinresistens DK3445354T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325381P 2016-04-20 2016-04-20
PCT/US2017/028417 WO2017184767A1 (en) 2016-04-20 2017-04-19 Azelaic acid esters in the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
DK3445354T3 true DK3445354T3 (da) 2022-08-29

Family

ID=60088670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17786579.7T DK3445354T3 (da) 2016-04-20 2017-04-19 Azelainsyreestere ved behandling af insulinresistens

Country Status (21)

Country Link
US (3) US10251857B2 (da)
EP (2) EP3445354B8 (da)
JP (2) JP7072762B2 (da)
KR (1) KR102233912B1 (da)
CN (1) CN109195597B (da)
AU (2) AU2017253088B2 (da)
CA (1) CA3021516C (da)
CY (1) CY1125499T1 (da)
DK (1) DK3445354T3 (da)
ES (1) ES2925775T3 (da)
HR (1) HRP20220988T1 (da)
HU (1) HUE059844T2 (da)
LT (1) LT3445354T (da)
NZ (1) NZ746669A (da)
PL (1) PL3445354T3 (da)
PT (1) PT3445354T (da)
RS (1) RS63558B1 (da)
SG (1) SG11201808367UA (da)
SI (1) SI3445354T1 (da)
SM (1) SMT202200351T1 (da)
WO (1) WO2017184767A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808367UA (en) * 2016-04-20 2018-10-30 New Frontier Labs Llc Azelaic acid esters in the treatment of insulin resistance
AU2021222580A1 (en) * 2020-02-19 2022-09-01 New Frontier Labs, Llc Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions
MX2023006727A (es) * 2020-12-16 2023-06-26 New Frontier Labs Llc Esteres de acidos dicarboxilicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d.
CA3202461A1 (en) * 2020-12-16 2022-06-23 Robert T. Streeper Dicarboxylic acid esters for inducing an analgesic effect
US20260048034A1 (en) 2024-08-15 2026-02-19 New Frontier Labs, Llc Compositions and methods for enhancing the efficacy of dicarboxylic acid esters, and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426683A1 (de) * 1974-06-01 1975-12-18 Boehringer Mannheim Gmbh Biguanide und verfahren zu deren herstellung
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
JP2003507036A (ja) * 1999-08-16 2003-02-25 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド レチノイドレセプター相互作用ポリヌクレオチド、ポリペプチド、および抗体
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
ES2339752T3 (es) * 2001-08-13 2010-05-25 Yale University Metodo para inducir una respuesta inmune selectivamente suprimida.
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US20080051373A1 (en) * 2003-07-31 2008-02-28 The Board Of Regents Of The University Of Texas System Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use
WO2006074379A2 (en) 2005-01-07 2006-07-13 Azaya Therapeutics, Inc. Methods and compositions involving esters of azelaic acid and other dicarboxylic acids
US8440217B1 (en) * 2005-06-15 2013-05-14 Mawaheb M. EL-Naggar Method and system with contact lens product for treating and preventing adverse eye conditions
US20070048371A1 (en) * 2005-07-28 2007-03-01 Shojaei Amir H Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
PT2100604E (pt) * 2008-03-10 2012-07-24 Nestec Sa Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas
WO2010005521A1 (en) * 2008-06-30 2010-01-14 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers
US20120251525A1 (en) * 2009-06-30 2012-10-04 Streeper Robert T Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
US9023887B2 (en) * 2011-04-15 2015-05-05 University of Pittsburgh—of the Commonwealth System of Higher Education Lipase inhibitors for the treatment of pancreatitis and organ failure
KR101593539B1 (ko) * 2015-07-03 2016-02-15 고려대학교 산학협력단 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물
SG11201808367UA (en) * 2016-04-20 2018-10-30 New Frontier Labs Llc Azelaic acid esters in the treatment of insulin resistance

Also Published As

Publication number Publication date
JP7072762B2 (ja) 2022-05-23
LT3445354T (lt) 2022-09-12
JP7088460B2 (ja) 2022-06-21
AU2017253088B2 (en) 2022-04-28
HRP20220988T1 (hr) 2022-11-11
CN109195597A (zh) 2019-01-11
EP3445354B1 (en) 2022-05-25
NZ746669A (en) 2022-10-28
HUE059844T2 (hu) 2023-01-28
US20210260014A1 (en) 2021-08-26
RS63558B1 (sr) 2022-10-31
AU2022203809B2 (en) 2024-02-22
US10251857B2 (en) 2019-04-09
SMT202200351T1 (it) 2022-09-14
EP3445354B8 (en) 2022-07-06
ES2925775T3 (es) 2022-10-19
US11026912B2 (en) 2021-06-08
EP3445354A1 (en) 2019-02-27
US20170304252A1 (en) 2017-10-26
CY1125499T1 (el) 2026-02-25
EP3445354A4 (en) 2020-01-01
US20190167627A1 (en) 2019-06-06
JP2019515895A (ja) 2019-06-13
CN109195597B (zh) 2021-08-24
AU2022203809A1 (en) 2022-06-23
AU2017253088A1 (en) 2018-10-18
WO2017184767A1 (en) 2017-10-26
CA3021516C (en) 2024-02-20
PL3445354T3 (pl) 2022-09-19
JP2021091709A (ja) 2021-06-17
PT3445354T (pt) 2022-08-25
KR20180133914A (ko) 2018-12-17
KR102233912B1 (ko) 2021-03-29
CA3021516A1 (en) 2017-10-26
US12329735B2 (en) 2025-06-17
SG11201808367UA (en) 2018-10-30
EP4085907A1 (en) 2022-11-09
SI3445354T1 (sl) 2022-10-28

Similar Documents

Publication Publication Date Title
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3233130T3 (da) Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom
IL257105A (en) Modified cells and methods of therapy
DK3341482T3 (da) Kunstige nukleinsyremolekyler
EP3347649A4 (en) CAMERA IN AN OVEN
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3294325T3 (da) Forbedring af virkningen af car-manipulerede t-celler ved hjælp af nukleinsyrevaccination
EP3311742A4 (en) BLOOD COLLECTORS
DK3808404T3 (da) Blodpumpe med selvspulende leje
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
IL256374B (en) Long-acting coagulation factors and methods of producing same
DK3393537T3 (da) Biomedicinske materialer med høj styrke
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3297654T3 (da) Behandling af post-bariatrisk hypoglykæmi med exendin(9-39)
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose